At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 815 enrolled
Drug / intervention
Elagolix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
In Brief
A Phase 3 clinical trial evaluating placebo and Elagolix for Endometriosis. Completed, enrolled 815 participants.
Detailed Summary
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 2013
Enrollment StartSep 2013
Primary CompletionJan 2016
Study CompletionDec 2016
TodayJul 2026
First PostedAug 29, 2013
Enrollment StartSep 9, 2013
Primary CompletionJan 6, 2016
Study CompletionDec 19, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 12.8 years ago
Interventions
placeboother
Elagolixdrug